After Plunging -31.47 percent in 4 Weeks, Heres Why the Trend Might Reverse for Prelude Therapeutics
PRLD Stock | USD 1.05 0.07 7.14% |
About 66 percent of all Prelude Therapeutics' shareholders are curious in acquiring. The analysis of the overall investor sentiment regarding Prelude Therapeutics suggests that quite a large number of traders are confidant. The current market sentiment, together with Prelude Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Prelude Therapeutics stock news signals to limit their universe of possible portfolio assets.
Prelude |
Prelude Therapeutics is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read at zacks.com
Prelude Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Prelude Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Prelude Therapeutics Fundamental Analysis
We analyze Prelude Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Prelude Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Prelude Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Prelude Therapeutics is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Prelude Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Prelude Therapeutics stock to make a market-neutral strategy. Peer analysis of Prelude Therapeutics could also be used in its relative valuation, which is a method of valuing Prelude Therapeutics by comparing valuation metrics with similar companies.
Peers
Prelude Therapeutics Related Equities
PASG | Passage Bio | 68.66 | ||||
ANTX | AN2 Therapeutics | 21.90 | ||||
GLUE | Monte Rosa | 13.72 | ||||
CCCC | C4 Therapeutics | 8.59 | ||||
NRIX | Nurix Therapeutics | 4.15 | ||||
BDTX | Black Diamond | 3.11 | ||||
FHTX | Foghorn Therapeutics | 2.57 | ||||
RZLT | Rezolute | 1.00 | ||||
STTK | Shattuck Labs | 0.92 | ||||
KYMR | Kymera Therapeutics | 0.02 | ||||
MOLN | Molecular Partners | 0.17 | ||||
PEPG | PepGen | 0.98 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
PHVS | Pharvaris | 2.06 | ||||
MLYS | Mineralys Therapeutics, | 2.59 | ||||
ELYM | Eliem Therapeutics | 5.88 |
Complementary Tools for Prelude Stock analysis
When running Prelude Therapeutics' price analysis, check to measure Prelude Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Prelude Therapeutics is operating at the current time. Most of Prelude Therapeutics' value examination focuses on studying past and present price action to predict the probability of Prelude Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Prelude Therapeutics' price. Additionally, you may evaluate how the addition of Prelude Therapeutics to your portfolios can decrease your overall portfolio volatility.
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
CEOs Directory Screen CEOs from public companies around the world | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |